The epidemiology of depression and the evolution of treatment

Journal of Clinical Psychiatry

Volumn 73, Issue SUPPL. 1, 2012, Pages 5-9

  Hirschfeld, Robert M A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CAMPHOR; CATECHOLAMINE; CHLORPROMAZINE; DULOXETINE; IMIPRAMINE; INSULIN; IPRONIAZID; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PENTETRAZOLE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGE DISTRIBUTION; BIPOLAR DEPRESSION; BRAIN HEMORRHAGE; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERTENSIVE CRISIS; LIVER FAILURE; LIVER TOXICITY; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84864852608     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11096su1c.01     Document Type: Review

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
2. Kessler RC, Birnbaum H, Bromet E, et al. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010;40(2):225-237. doi:10.1017/S032917090213 PubMed
3. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809-816. doi:10.101/archpsyc.192.018201053010 PubMed
4. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-1006. PubMed
5. Fichter MM, Kohlboeck G, Quadflieg N. The Upper Bavarian longitudinal community study 1975-2004, pt 2: long-term course and outcome of depression: a controlled study. Eur Arch Psychiatry Clin Neurosci. 2008;258(8):476-488. doi:10.107/s0406-08-0821-z PubMed
6. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694-700. doi:10.101/archpsyc.5.8.694 PubMed
7. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2008. http://www.who.int/healthinfo/global- burden-disease/GBD-report-2004update-full.pdf. Accessed February 20, 2012.
8. Fiedorowicz JG, Endicott J, Leon AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011;168(1):40-48. doi:10.176/api.ajp.2010.1030328 PubMed
9. American Psychiatric Association. DSM-5 development: depressive disorders. http://www.dsm5.org/ProposedRevision/Pages/DepressiveDisorders.aspx. Published 2012. Accessed April 17, 2012.
10. Fink M. Meduna and the origins of convulsive therapy. Am J Psychiatry. 1984;141(9):1034-1041. PubMed
11. Sabbatini RME. The history of shock therapy in psychiatry. Brain Mind Electron Mag Neurosci. 1997;4. http://www.cerebromente.org.br/n04/historia/ shock-i.htm. Accessed April 17, 2012.
12. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929-1950. J Hist Med Allied Sci. 2006;61(3):288-323. doi:10.1093/jhmas/jrj039 PubMed
13. Guttmann E, Sargant W. Observations on Benzedrine. BMJ. 1937;1(3984):1013-1015. doi:10.136/bmj.1.3984.1013 PubMed
14. Callahan CM, Berrios GE. Reinventing Depression: A History of the Treatment of Depression in Primary Care, 1940-2004. New York, NY: Oxford University Press; 2005.
15. Nelson JC. Tricyclic and tetracyclic drugs. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Press, Inc; 2009:263-288.
16. Nasrallah HA, Tandon R. Classic antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:533-554.
17. Frankenburg FR, Baldessarini RJ. Neurosyphilis, malaria, and the discovery of antipsychotic agents. Harv Rev Psychiatry. 2008;16(5):299-307. doi:10.1080/1067320802432350 PubMed
18. Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335-344. PubMed
19. Crane GE. The psychiatric side-effects of iproniazid. Am J Psychiatry. 1956;112(7):494-501. PubMed
20. Rosenblum LE, Korn RJ, Zimmerman HJ. Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med. 1960;105(4):583-593. doi:10.101/archinte.1960.027016081010 PubMed
21. Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:389-402.
22. Atchley DW. Reevaluation of tranylcypromine sulfate. JAMA. 1964;189(10):763-764. doi:10.101/jama.1964.03070105701 PubMed
23. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10(4):239-248. doi:10.1097/0131746-204070-05 PubMed
24. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509-522. PubMed
25. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(suppl 4):4-11, discussion 12-13. PubMed
26. Golden RN, Dawkins K, Nicholas L. Trazodone and nefazodone. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:403-414.
27. Clayton AH, Gillespie EH. Bupropion. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:415-428.
28. Zahajszky J, Rosenbaum JF, Tollefson GD. Fluoxetine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:289-306.
29. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65(suppl 4):5-10. PubMed
30. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27. doi:10.408/PC.v03n0105 PubMed
31. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998;279(7):526-531. doi:10.101/jama.279.7.526 PubMed
32. Jain R. Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 1):7-11. PubMed
33. Thase ME, Sloan DM. Venlafaxine and desvenlafaxine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:439-452.
34. Norris S, Blier P. Duloxetine and milnacipran. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Arlington, VA: American Psychiatric Publishing; 2009:453-464.